No articles found for this sector...

================================================================================

No articles found for this sector...

================================================================================

[TITLE]Digital Transformation in Healthcare Market Size to Reach USD 258.22 Billion by 2033 Driven by Technology Adoption and Patient Centric Care – SNS Insider:
[TEXT]
Austin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- According to S&S Insider, the global Digital Transformation in Healthcare
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192874/0/en/Digital-Transformation-in-Healthcare-Market-Size-to-Reach-USD-258-22-Billion-by-2033-Driven-by-Technology-Adoption-and-Patient-Centric-Care-SNS-Insider.html


[TITLE]Asthma and COPD Drugs Market to Reach USD 50.42 Billion by 2033, Driven by Rising Prevalence of Respiratory Disorders and Growing Adoption of Combination Therapies – SNS Insider:
[TEXT]
Austin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- Asthma and COPD Drugs
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192846/0/en/Asthma-and-COPD-Drugs-Market-to-Reach-USD-50-42-Billion-by-2033-Driven-by-Rising-Prevalence-of-Respiratory-Disorders-and-Growing-Adoption-of-Combination-Therapies-SNS-Insider.html


[TITLE]BK Virus Infection Market Trends, Strategies and Business Prospects 2025-2035 - Lack of FDA-Approved Drugs Spurs Innovation in BK Virus Treatment:
[TEXT]
Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "BK Virus Infection Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.

The key drivers propelling the BK virus infection drug market stem largely from the growing immunocompromised patient population. Organ transplantation, particularly kidney transplants, is increasing globally. For instance, the United Network for Organ Sharing (UNOS) reported over 23,000 kidney transplants in the US alone in 2023, a population highly vulnerable to BKV reactivation. This surge directly increases the demand for effective management of BKV infections.

Furthermore, awareness of BKV-related complications among nephrologists and transplant surgeons has risen, leading to routine BKV screening post-transplant, which further stimulates the market for therapeutic drugs. Off-label use of antivirals such as cidofovir and leflunomide remains prevalent despite their nephrotoxicity and limited efficacy, underscoring the urgent need for targeted drug development. Additionally, widespread immunosuppressive regimens, essential to prevent graft rejection, inadvertently increase susceptibility to BKV reactivation, making antiviral treatment options a critical unmet need.

Despite growing awareness and demand, several challenges constrain the BK virus infection drug market. Foremost is the absence of FDA-approved antiviral agents specifically targeting BKV, which forces clinicians to rely on off-label medications. Both drugs, while somewhat effective, are associated with significant side effects; for example, nephrotoxicity can exacerbate kidney damage, a grave concern for transplant patients.

Managing the delicate balance between reducing immunosuppression to control the virus and maintaining sufficient immunosuppression to prevent graft rejection adds complexity to treatment protocols, making standardized drug regimens elusive. Financial barriers also exist high costs associated with frequent viral load monitoring and long-term therapy can restrict access, especially in resource-limited settings such as parts of Southeast Asia and Africa, where transplant infrastructure is growing but limited.

However, the BK virus infection market holds several promising opportunities for innovation and growth. Drug developers are increasingly focusing on creating targeted antiviral agents that inhibit specific stages of BKV replication, potentially improving efficacy while minimizing side effects. For example, AlloVir is advancing adoptive T-cell therapies that harness the patient's immune cells to specifically attack BKV-infected cells a personalized treatment approach showing encouraging early clinical results. This form of immunotherapy could revolutionize BKV management, reducing dependence on toxic antivirals.

Additionally, integrating companion diagnostics with therapeutic regimens presents an opportunity for precision medicine; real-time viral load tracking via sensitive PCR assays allows clinicians to tailor therapy intensity, improving patient outcomes. Combination therapies that pair antivirals with immune modulators are also under exploration, aiming to simultaneously suppress viral replication and optimize immune response. Market expansion in emerging economies is noteworthy. This expanding transplant ecosystem, combined with increasing healthcare investments, creates fertile ground for introducing novel BKV therapies.

Moreover, market trends reflect broader shifts in medical innovation and healthcare delivery. Precision medicine is becoming central to BKV management, with clinicians tailoring treatment based on viral load measurements and patient-specific immune profiles. For example, many transplant centers in the U.S. and Europe have adopted routine BKV viral load monitoring protocols to guide immunosuppressant adjustments and antiviral use, minimizing overtreatment.

Investment in immunotherapies like adoptive T-cell therapy is growing, reflecting confidence in cell-based approaches to control persistent viral infections. The use of biomarkers and molecular diagnostics is influencing not only clinical practice but also drug development pipelines, with pharmaceutical companies increasingly developing integrated solutions that combine diagnostics with therapeutics. Collaborations between biotech firms and leading transplant centers, such as the partnership between AlloVir and academic institutions, accelerate clinical trials and validation.

The current therapeutic landscape is dominated by off-label use of antivirals like cidofovir and leflunomide. Despite their limitations, these drugs remain the mainstay of BKV treatment due to the absence of approved alternatives. For example, a multicenter study in Europe highlighted the cautious use of leflunomide to reduce viral load but also noted significant side effects limiting broader adoption.

Emerging players such as AlloVir are shifting the paradigm by developing adoptive T-cell therapies that target BKV with high specificity, positioning themselves as leaders in immunotherapeutic innovation. Large pharmaceutical companies are also exploring antiviral candidates with activity against polyomaviruses, seeking to fill the gap in approved treatments.

Market Dynamics:

Drivers Increasing incidences of BK virus infections among organ transplant recipients. Rising awareness and advancements in diagnostic technologies. Growing demand for effective antiviral drugs.

Challenges Lack of effective treatment options currently available in the market. High costs associated with the development of new therapeutics.

Case Studies Implementation of new diagnostic standards in the U.S. hospitals.

Industry Trends Focus on personalized medicine and targeted therapies for BK virus infections.

Opportunities Expansion of research and development for novel therapeutic solutions. Potential market growth in emerging economies due to rising healthcare infrastructure.

Company Profiles:

Kalaris Therapeutics (AlloVir)

Hybridize Therapeutics

Orthogon Therapeutics

Vera Therapeutics, Inc.

AiCuris

Memo Therapeutics AG

SymBio Pharmaceuticals Limited
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192888/28124/en/BK-Virus-Infection-Market-Trends-Strategies-and-Business-Prospects-2025-2035-Lack-of-FDA-Approved-Drugs-Spurs-Innovation-in-BK-Virus-Treatment.html


[TITLE]Alcoholic Hepatitis Market Analysis and Forecast, 2025-2035 - Innovative Therapies, TNF Inhibitors and Stem Cell Treatments, are on the Horizon:
[TEXT]
Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "Alcoholic Hepatitis Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.

The global alcoholic hepatitis market is primarily driven by the increasing prevalence of global alcohol consumption, rising alcohol-related liver diseases, and increased public awareness of liver health. Advancements in diagnostic methods and early screening programs have improved the identification and management of this condition, prompting a growing demand for more effective therapies.

Current treatment strategies primarily include corticosteroids and nutritional support; however, research is advancing toward the development of novel anti-inflammatory agents, biologics, and targeted molecular therapies. Emerging approaches such as TNF inhibitors and stem cell therapies are also being explored, offering new virtues to improve patient outcomes.

However, the market does face challenges such as the absence of disease-specific treatments, which restricts therapeutic options and leads to variability in clinical outcomes. Moreover, social stigma and underdiagnosis of alcohol use disorders can delay patient access to care.

On the other hand, growth opportunities are emerging from expanding access to treatment in developing countries, where healthcare infrastructure is improving and public health initiatives are addressing alcohol-related harm. Further, pharmaceutical companies are actively investing in research and development to address unmet needs and improve therapeutic outcomes, which is expected to drive innovation and long-term growth in the alcoholic hepatitis market landscape.

Industrial Impact

Technological advancements in drug development, diagnostics, and patient monitoring solutions are driving progress in the alcoholic hepatitis market. Emerging therapies and non-invasive diagnostic tools are improving early detection, treatment outcomes, and long-term disease management, especially in severe cases.

Demand Drivers for the Global Alcoholic Hepatitis Market:

Increasing global incidence of alcohol-related liver diseases, particularly in regions with high alcohol consumption

Heightened public awareness of liver health and expanded screening initiatives promote earlier medical engagement

High relapse and readmission rates necessitate long-term disease management, creating sustained demand for pharmacological and supportive care

Limitations for the Global Alcoholic Hepatitis Market:

Limited access to liver specialists and advanced treatment options in emerging markets

Stigma associated with alcohol-related diseases can lead to underdiagnosis and poor treatment adherence, thereby hindering the market growth.

How can this report add value to an organization?

Product/Innovation: This report provides comprehensive insights into the current trends in alcoholic hepatitis, helping companies identify opportunities for drug and technology development. Organizations can leverage these insights to design therapies, medications, and platforms tailored to the needs of patients suffering from alcoholic hepatitis, improving outcomes and enhancing market penetration.

Competitive: A detailed competitive landscape analysis helps organizations benchmark their market standing against key players such as Aldeyra Therapeutics and Intercept Pharmaceuticals. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global alcoholic hepatitis market.

Key Market Players and Competition Synopsis

The companies profiled in this report have been selected based on their market presence, product portfolio, and competitive positioning in the global alcoholic hepatitis market. Leading players in the global alcoholic hepatitis market include:

Aldeyra Therapeutics

Intercept Pharmaceuticals, Inc.

DURECT Corporation

Market Dynamics:

Drivers: The increasing prevalence of alcoholic hepatitis globally. Advancements in treatment options and medical research. Rising awareness and early diagnosis campaigns.

Challenges: Lack of effective therapeutic options. High cost of treatment and healthcare services. Social stigma and lack of awareness.

Case Studies: Successful intervention programs in North America. Community health initiatives in Europe.

Industry Trends: Growing partnerships and collaborations in the healthcare sector. Increased investment in R&D for alcoholic hepatitis.

Opportunities: Development of innovative therapies and drugs. Expansion into emerging markets.

Company Profiles:

Aldeyra Therapeutics, Inc. Company Overview Product Portfolio Target Customers/End Users Analyst View

Alfasigma Group (Intercept Pharmaceuticals, Inc.) Company Overview Product Portfolio Target Customers/End Users Analyst View

DURECT Corporation Company Overview Product Portfolio Target Customers/End Users Analyst View
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192883/28124/en/Alcoholic-Hepatitis-Market-Analysis-and-Forecast-2025-2035-Innovative-Therapies-TNF-Inhibitors-and-Stem-Cell-Treatments-are-on-the-Horizon.html


===== Company info for companies mentioned in news =====

Company name: anaptysbio
symbol: ANAB
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1763860491
name: anaptysbio
------------------------------------------------------------------

Company name: gsk
symbol: GSK
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1763860492
name: gsk
------------------------------------------------------------------

Company name: jp morgan
name: jp morgan
symbol: None
note: no reliable listing found
------------------------------------------------------------------

Company name: supernus pharmaceuticals
name: supernus pharmaceuticals
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=supernus+pharmaceuticals&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

================================================================================

[TITLE]Oncology Biomarker Market Accelerates Toward USD 113.5 Billion by 2034:
[TEXT]
Ottawa, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The global oncology biomarker
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192889/0/en/Oncology-Biomarker-Market-Accelerates-Toward-USD-113-5-Billion-by-2034.html


[TITLE]Biotechnology CMO and CDMO Market on Track for USD 199.67 Billion by 2034 with a Strong 11.54% CAGR:
[TEXT]
Ottawa, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The global biotechnology CMO and CDMO
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192861/0/en/Biotechnology-CMO-and-CDMO-Market-on-Track-for-USD-199-67-Billion-by-2034-with-a-Strong-11-54-CAGR.html


[TITLE]Anti-Nuclear Antibody (ANA) Testing Global Market Overview 2025:
[TEXT]
Dublin, Nov. 21, 2025 (GLOBE NEWSWIRE) -- The "Anti-Nuclear Antibody (ANA) Testing - A Global Market Overview" report has been added to ResearchAndMarkets.com's offering.

The global Antinuclear Antibody (ANA) Testing market is forecast to expand from US$2.1 billion in 2025 to US$4.9 billion by 2032, advancing at a CAGR of 12.5%.

This global report on Antinuclear Antibody (ANA) Testing analyzes the global and regional markets based on product, technique, application, and end user for the period 2022-2032 with projections from 2025 to 2032 in terms of value in US$. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing.

Growth is primarily fueled by the rising global prevalence of autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, and Sjogren's syndrome, which are driving the demand for reliable and sensitive diagnostic tools. Public health campaigns and educational programs have raised awareness
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192570/28124/en/Anti-Nuclear-Antibody-ANA-Testing-Global-Market-Overview-2025.html


[TITLE]NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward:
[TEXT]
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring invaluable clinical development expertise to VIS-101 Program

The ability to attract seasoned ophthalmology leaders highlights the compelling opportunity for VIS-101, and underscores our commitment to assembling a world-class team

VIS-101, a novel bifunctional biologic targeting VEGF-A/ANG2, has the potential to become the current standard for wet AMD, DME and RVO, and is expected to be Phase-3-ready in 2026

ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, today announced that its subsidiary Visara, Inc. (Visara) has appointed Cadmus C. Rich, MD, MBA, as its Chief Medical Officer (CMO), and Carlos Quezada-Ruiz MD, FASRS, as Chairman of its Scientific Advisory Board (SAB). As CMO, Dr. Rich will be responsible for overseeing all of the clinical functions and programs for Visara. Dr. Quezada-Ruiz will chair Visara’s newly formed SAB.

“Dr. Rich and Dr. Quezada-Ruiz are each exceptional ophthalmologists and drug development leaders across global markets. Their appointments validate the exciting opportunity for VIS-101 and demonstrate Visara’s commitment to building a world class organization. Dr. Rich is a skilled ophthalmology professional and accomplished drug development executive with proven expertise in pioneering cutting-edge programs across the R&D and regulatory landscapes,” said Emmett T. Cunningham, Jr., MD, PhD, MPH, Co-Founder and Executive Chairman of Visara. “Dr. Quezada-Ruiz is an internationally recognized retina specialist and clinical scientist who has played a pivotal role in the development of novel technologies and therapies for retinal disease, including the development, global regulatory filings, and approvals of VABYSMO® for wet AMD. I am thrilled to welcome Dr. Rich and Dr. Quezada-Ruiz to Visara and believe they will each make invaluable contributions to our success.”

“I am passionate
[Source link]: https://www.globenewswire.com/news-release/2025/11/21/3192485/0/en/NovaBridge-s-Visara-Subsidiary-Appoints-Distinguished-Ophthalmology-Leaders-as-Chief-Medical-Officer-and-Scientific-Advisory-Board-Chair-to-Drive-VIS-101-Forward.html


===== Company info for companies mentioned in news =====

Company name: adlai nortye
symbol: N2U0.F
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1763860494
name: adlai nortye
------------------------------------------------------------------

Company name: oncotelic therapeutics
name: oncotelic therapeutics
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=oncotelic+therapeutics&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

Company name: pasithea therapeutics
name: pasithea therapeutics
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=pasithea+therapeutics&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

Company name: xoma royalty
symbol: XOMA
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1763860495
name: xoma royalty
------------------------------------------------------------------

================================================================================

No articles found for this sector...

================================================================================

